30. Genetics and synthetic biology for trailblazing drug discovery, Maria Soloveychik, CEO, SyntheX

30. Genetics and synthetic biology for trailblazing drug discovery, Maria Soloveychik, CEO, SyntheX

Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in 2016 and is located in San Francisco. Maria has obtained her PhD from the Department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium at the University Health Network in Toronto, where her work led to the determination of numerous structures and identification of several drug candidates.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Jun 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Mai 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mar 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Mar 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Feb 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Feb 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Jan 21min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
sinnsyn
forskningno
liberal-halvtime
vett-og-vitenskap-med-gaute-einevoll
villmarksliv
rekommandert
rss-paradigmepodden
jss
fjellsportpodden
rss-rekommandert
rss-inn-til-kjernen-med-sunniva-rose
kvinnehelsepodden
tomprat-med-gunnar-tjomlid
grunnstoffene
aldring-og-helse-podden
hva-er-greia-med
diagnose
dekodet-2